References

  1. Kessler, D. A., Siegel, J. P., Noguchi, P. D, et al. (1993). Regulation of somatic-cell therapy and gene therapy by the Food and Drug Administration. N. Engl. ]. Med. 329, 1169-1173.
  2. Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines) (January 2001). Available at http://www4.od.nih.gov/oba/rac/guidelines/guidelines.html.
  3. Center for Drug Evaluation and Research. (September 1989). "Guideline for Drug Master Files."
  4. Food and Drug Administration, Center for Biologies Evaluation and Research (March 1998). "Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy." Available at http://www.fda.gov/cber/guidelines.
  5. (1993). "Points to Consider in the Characterization of Cell lines Used to Produce Biologicals." Available at http://www.fda.gov/cber/guidelines.
  6. Federal Register Notice of Availability (September 9, 1998). "International Conference on Harmonisation: Guidance on Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin; Availability." 63 FR 51074.
  7. WBF and CBER websites for Adenovirus Reference Material Working Group, Bid proposals and meeting minutes/transcripts www.wilbio.com and www.cber.fda.gov.
  8. "Biologies Response Modifiers Advisory Committee Meeting, Nov. 16-17, 2000." Transcripts available at www.cber.fda.gov.
  9. "Biologies Response Modifiers Advisory Committee Meeting April 5-6, 2001." Transcripts available at www.cber.fda.gov.
  10. "Biologies Response Modifiers Advisory Committee Meeting Oct. 24-26,2001." Transcripts available at www.cber.fda.gov.
  11. Shabram, P., and Aguilar-Cordova, E. (2000). Multiplicity of infection/multiplicity of confusion. Mol. Ther. 2, 420-421.
  12. Hutchins, B., Sajjadi, N., Seaver, S., Shepherd, A., Bauer, S. R., Simek, S., Carson, K., and Aguilar-Cordova, E. (2000). Working toward an adenoviral vector testing standard. Mol. Ther. 2, 532-534.
  13. International Conference on Harmonisation (July 1997). "Guidance for Industry. S6: Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals." Available at http://www. fda.gov/cber/guidelines.
  14. Crystal, R. G., McElvaney, N. G., Rosenfeld, M. A., Chu, C. S., Mastrangeli, A., Hay, J. G., Brody, S. L., Jaffe, H. A., Eissa, N. T., and Danel, C. (1994). Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat. Genet. 8, 42-51.
  15. Recombinant DNA Advisory Committee Meeting http://www4.od.nih.gov/oba/3-99RAC. htm
  16. Pilaro, A. M., and Serabian, M. A. (1999). Preclinical development strategies for novel gene therapeutic products. Toxicol. Pathol. 27, 4-7.
  17. International Conference on Harmonisation. "Guidance for Industry. E6: Good Clinical Practice: Consolidated Guidance." Available at http://www.fda.gov/cber/guidelines.
  18. International Congress on Harmonisation. "Guidance for Industry. E3: Structure and Content of the Final Study Report." Available at http://www.fda.gov/cber/guidelines.
  19. International Congress on Harmonisation. "The Common Technical Document." Available at http://www.fda.gov/cber/guidelines.
  20. Kessler, D. A. (1993). MedWatch: The new FDA medical products reporting program Am. J. Hosp. Pharm. 50, 1151-1152.
  21. "Additional Safeguards for Children in Clinical Investigations of FDA-Regulated Industry Products. Interim Rule." Available at http://www.fda.gov/OHRMS/DOCKETS/98fr/ cd0030.pdf.
  22. International Conference on Harmonisation. "Ell: Clinical Investigation of Medicinal Products in the Pediatric Population." Available at http://www.fda.gov/cber/guidelines.
  23. Wittes, J. (1993). Behind closed doors: The data monitoring board in randomized clinical trials. Stat. Med. 12,419-424.
  24. Trask, T. W., Trask, R. P., Aguilar-Cordova, E., Shine, D., Wyde, P. R., Goodman, J. C., Hamilton, W. J., Rojas-Martinez, A., Chen, S. H., Woo, S. L., and Grossman, R. G. (2000). Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol. Ther. 1, 195-203.
  25. Kafri, T., Morgan, D., Krahl, T., Sarvetnick, N., Sherman, L., and Verma, I. (1998). Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: Implications for gene therapy. Proc. Natl. Acad. Sci. USA 95, 1377-1382.
  26. Recombinant DNA Advisory Committee. "Minutes of Symposium and Meeting, December 8-10, 1999." Available at: http://www4.od.nih.gov/oba/rac/meeting.html.
  27. "Testing for Replication Competent Retrovirus in Retroviral Based Gene Therapy Products and During Follow up of Patients in Clinical Trials using Retroviral Vectors, October 18, 2000." Available at http://www.fda.gov/cber/guidelines.
  28. International Conference on Harmonisation. "Guidance for Industry. ElO: Choice of Control." Available at http://www.fda.gov/cber/guidelines.
  29. Fleming, T. R. (1994). Surrogate markers in AIDS and cancer trials Stat. Med. 13, 1423-1435.
  30. Fleming, T. R., and DeMets, D. L. (1996). Surrogate Endpoints in Clinical Trials: Are We Being Misled? Ann. Intern. Med. 125, 605-613.
  31. "Guidance for Industry: Providing Clinical Evidence of Effectiveness, May 1998." Available at http://www.fda.gov/cber/guidelines.
  32. NIH Report. Assessment of adenoviral vector safety and toxicity: Report of the National Institutes of Health Recombinant DNA Advisory Committee (2002). Hum. Gene Ther. 13, 3-13.
  33. Warning Letters http://www.fda.gov/cber/efoi/warning01.htm and http://www.fda.gov/foi/ warning-letters.
  34. Notice of Intent at http://www.fda.gov/foi/nidpoe/default.html.
  35. Mcintosh, K. (1990). Diagnositc virology. In "Fields Virology" (B.N. Fields and D.M. Knipe, Eds.), 2nd ed., Raven Press, Chap. 17, pp. 383-410. New York.
  36. Wagner, R. (1990). Rhabdoviridae and their replication. In "Fields Virology" (B. N. Fields and D. M. Knipe, Eds.), 2nd ed., Raven Press, Chap. 31, pp. 867-883. New York.

CHAPTER

Was this article helpful?

0 0

Post a comment